Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
about
Lymphatic disorders after renal transplantation: new insights for an old complicationEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.Review on immunosuppression in liver transplantation.A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.The role of everolimus in liver transplantation.Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.Immunological risks of minimization strategies.A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients.Regulatory T cells: first steps of clinical application in solid organ transplantation.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Perioperative Management of Cardiac Transplant Recipients Undergoing Noncardiac Surgery: Unique Challenges Created by Advancements in Care.Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients.Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients.The Effect of Mycophenolate Mofetil on Early Wound Healing in a Rodent Model.Everolimus-associated perianal ulcers in an eight-month-old heart transplant recipient.Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART.De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation.Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trialsEarly urological complications after kidney transplantation: An overview
P2860
Q26785848-14513DD6-C4BE-4202-914E-55E1742E6770Q30871643-F6FB18B6-69B1-45A6-BD7E-85EA288945D8Q34796915-E144AC41-1E8D-4B9B-9CCD-F1D5603BAA4DQ35232357-031EDB70-B66A-4A52-8C8B-056D8ACCC124Q35668757-4BE9112A-103B-41BB-9A4F-1D1864B6556FQ35805955-53C756EA-0E46-4BB4-8BE2-421AB8689451Q37184425-B936180B-F14B-43BE-8A25-5E9BFE0E7145Q37605371-75291595-00AF-4012-8F87-2056A8150EAEQ38043510-75F3E2EA-E896-4113-A5CD-247C235B7C11Q38241710-9C138DAD-CDEC-41EF-96FB-8F5F062827D5Q38248591-319D95A9-8FD3-4987-9C0C-09BFB7E73E46Q38268775-2ACAF380-7428-4F0E-BB9C-3FE7D6423F80Q38391150-0481E54A-A725-4675-AD90-FFFF544720C9Q38395489-38AD1DB3-2ED7-4763-ACB4-E2175482FD48Q38485004-7C14F03C-0BA7-4E3C-8888-2754C5846ED6Q38711763-C665A8C9-1A27-4912-9CA2-946F6954DC7CQ38807449-7DBF1025-FCAB-442F-AC66-5C4E20812A21Q38992157-94D86FF5-CE64-4E1C-BF31-1DFA23F46B7CQ40073566-FBCE957E-2B1F-407F-A236-3DE2D153E7FEQ40634263-F3DE9FD4-F6E5-468E-8F0B-FE04074D4463Q42156439-1217A8FF-02D5-4846-A01D-108E2203FAFFQ48137288-660E1111-C95A-428C-876F-C1E20474F583Q49990142-42A07B3E-3731-48A5-9052-73E38C8909D9Q50111156-0A05B055-5601-4270-BFD9-DCD91316C9CDQ54335179-D6DDCE17-1F3E-4EC1-BB9D-637CAABF70B9Q55265769-390E8CC4-E7B5-45BF-8E76-86F449CF7AF3Q57793035-7657E6D4-D58D-47E1-90E8-1A8A21D81113Q58754935-0500F307-2A3B-4079-91BF-2B5ECA73E3CC
P2860
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Do wound complications or lymp ...... f randomized controlled trials
@ast
Do wound complications or lymp ...... f randomized controlled trials
@en
Do wound complications or lymp ...... f randomized controlled trials
@nl
type
label
Do wound complications or lymp ...... f randomized controlled trials
@ast
Do wound complications or lymp ...... f randomized controlled trials
@en
Do wound complications or lymp ...... f randomized controlled trials
@nl
prefLabel
Do wound complications or lymp ...... f randomized controlled trials
@ast
Do wound complications or lymp ...... f randomized controlled trials
@en
Do wound complications or lymp ...... f randomized controlled trials
@nl
P2093
P2860
P31
P3181
P1476
Do wound complications or lymp ...... f randomized controlled trials
@en
P2093
Liang Q. Liu
Liset H. M. Pengel
Peter J. Morris
P2860
P304
P3181
P356
10.1111/J.1432-2277.2011.01357.X
P407
P577
2011-12-01T00:00:00Z